SCHEMBL3384126

SCHEMBL3384126

CC(C)(C)OC(=O)N1C2CCCC1CN(c1ccc3cc([N+](=O)[O-])ccc3n1)C2

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
SLC6A4 P31645 1/20 0.47
CYP2C19 P33261 1/20 0.47
THPO P40225 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
LMNA P02545 2/20 0.46
PMP22 Q01453 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTR1A P08908 5/20 0.43
MAPT P10636 1/20 0.41
PDE10A Q9Y233 3/20 0.41
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542103 0.96 ALDH1A1 (0.49) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL4688608 0.85 ALDH1A1 (0.54) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL3386080 0.83 ALDH1A1 (0.58) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL21526485 0.79 HDAC1 (0.55) ALDH1A1CYP1A2LMNANPSR1MAPT
SCHEMBL3540666 0.78 ALDH1A1 (0.60) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL4846041 0.77 PARP1 (0.51) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL18186228 0.77 ALDH1A1 (0.51) ALDH1A1LMNAMAPT
SCHEMBL27480804 0.77 ALDH1A1 (0.57) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL5873711 0.77 PDE10A (0.55) ALDH1A1HTR3EHTR3BCYP1A2CYP3A4
SCHEMBL30533308 0.75 HDAC1 (0.49) ALDH1A1LMNAMAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984366-B1 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-12-15 EP disclosed
US-7687517-B2 3,9-Diazabicyclo [3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-03-30 US disclosed
US-20080306078-A1 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors DANPET AB (SE) 2008-12-11 US disclosed
EP-1984366-A1 3, 9-DIAZABICYCLO Ý3.3. 1¨NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-10-29 EP disclosed
WO-2007090887-A1 3, 9-DIAZABICYCLO [3.3. 1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE?NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306078-A1 3,9-Diazabicyclo [3.3.1] Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC18A3 ALDH1A1 608/4885HTR3E 67/4885HTR3B 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.